In the network, ESR1 (Estrogen Receptor) was the target with the highest degree (DD = 11), followed by NR3C1 (Glucocorticoid receptor, DD = 10), PLA2G2A (Phospholipase A2 group IIA, DD = 8), AR (Androgen Receptor, DD = 8), CYP2A6 (Cytochrome P450 2A6, DD = 7), CYP1B1 (Cytochrome P450 1B1, DD = 6) and etc. Evidence suggests that the potential active compounds in SHD can act on these targets, thus contributing to therapeutic effect on stomach diseases. Here, PLA2G2A is linked to stomach disorder.